
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Mohammad Razaq, MD, discusses how the detection of driver mutations has changed the way treatment is approached in advanced non–small cell lung cancer.























Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
5













































